Abstract
We read with interest the article by Patel et al. on the identification of potential inhibitors of coronavirus hemagglutinin-esterase. The authors considered hemagglutinin-esterase as a glycoprotein of SARS-CoV-2 and selected hemagglutinin-esterase as a target to identify potential inhibitors using a combination of various computational approaches, and however, SARS-CoV-2 genome lacks hemagglutinin-esterase gene; thus, hemagglutinin-esterase does not exist in SARS-CoV-2 particle.
Graphic abstract
In December 2019, a novel betacoronavirus “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2) detected in China [1]. SARS-CoV-2 is a member of Coronaviridae family. There are four genera in coronaviruses apha-, beta-, gamma- and deltacoronavirus [2]. Betacoronavirus genera is classified into five subgenera or lineages (Table 1) [3]. SARS-CoV-2 is a positive-sense single-strand RNA virus, and the size of its genome is about 30 kb [4]. The 2/3 of genome of SARS-CoV-2 at 5′ end contains two overlapping open reading frames (ORF1a and ORF1b) which encode two polyprotein precursors including pp1a and pp1b, respectively. Two proteases cleave both pp1a and pp1b to produce non-structural proteins. The remaining 3′ third of the genome encodes four structural proteins including spike (S), envelope (E), matrix (M) and nucleocapsid (N), and also, accessory genes are distributed in among the structural genes[4, 5]. Novel coronavirus (n-CoV) as a betacoronavirus of lineage B does not contain hemagglutinin-esterase (HE) [6,7,8,9,10]. However, betacoronaviruses of lineage A (such as OC43-CoV, HKU1-CoV and Bovine-CoV) harbor HE gene which encodes HE that acts as a receptor-destroying enzyme [11]. Some studies mistakenly reported that SARS-CoV-2 contains HE. Duner et al. stated that some coronaviruses including SARS-COV-2 contain HE [12], and however, they cited a reference which is published in 1998 Aug [13], although SARS-CoV-2 is detected in 2019 Dec and lacks HE. In another article, authors reported that betacoronavirus mostly uses HE to link to sialic acid on the glycoprotein surface [14], and however, betacoronavirus is a genera (Table 1) and among betacoronaviruses, viruses which belong to Embecovirus subgenera can code HE as a glycoprotein surface [15]. Aktas A et al. examined the biological activity of Arbidol in the inhibition of HE and spike glycoproteins of SARS-CoV-2 in silico[16], but according to scientific evidences which are described above, SARS-CoV-2 codes four structural proteins including spike, envelop, membrane and nucleoprotein [17], and therefore, Arbidol has no such interaction with HE in SARS-CoV-2 infection.
Recently in a published research article, authors presented that genome of SARS-CoV-2 harbors hemagglutinin-esterase gene and encodes HE glycoprotein, authors considered HE as a target for designing drug against SARS-CoV-2 infection [18], however, according to evidence SARS-CoV-2 genome lacks HE gene and cannot encode HE protein.
References
Lai CC et al (2020) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents 55(3):105924
Li H et al (2020) Coronavirus disease 2019 (COVID-19): current status and future perspectives. Int J Antimicrob Agents 55(5):105951
Wong AC et al (2019) Global epidemiology of bat coronaviruses. Viruses 11(2):174
Rastogi M et al (2020) SARS coronavirus 2: from genome to infectome. Respir Res 21(1):1–15
Kelly JA et al (2020) Structural and functional conservation of the programmed−1 ribosomal frameshift signal of SARS coronavirus 2 (SARS-CoV-2). J Biol Chem 295(31):10741–10748
Shi C-S et al (2019) SARS-Coronavirus Open Reading Frame-8b triggers intracellular stress pathways and activates NLRP3 inflammasomes. Cell Death Discov 5(1):1–12
Kumar S et al. (2020) Morphology, genome organization, replication, and pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Coronavirus Disease 2019 (COVID-19), p. 23
Devasena T (2021) The nanotechnology-COVID-19 Interface. Nanotechnology-COVID-19 interface. Springer, Singapore, pp 31–58
Crawford KH et al (2020) Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 spike protein for neutralization assays. Viruses 12(5):513
Zandi M, Behboudi E, Soltani S (2021) Role of glycoprotein hemagglutinin-esterase in COVID-19 pathophysiology? Stem Cell Rev Reports 28:1–2
Lang Y et al (2020) Coronavirus hemagglutinin-esterase and spike proteins coevolve for functional balance and optimal virion avidity. Proc Natl Acad Sci 117(41):25759–25770
Duner P, Salehi A (2020) COVID-19 and possible pharmacological preventive options. J Clin Med Res 12(12):758
De Haan CA et al (1998) Coronavirus particle assembly: primary structure requirements of the membrane protein. J Virol 72(8):6838–6850
Frediansyah A et al (2020) Antivirals for COVID-19: a critical review. Clin Epidemiol Glob Health 9:90–98
Kim C-H (2020) SARS-CoV-2 evolutionary adaptation toward host entry and recognition of receptor O-Acetyl sialylation in virus–host interaction. Int J Mol Sci 21(12):4549
Aktas A et al (2020) How do arbidol and its analogs inhibit the SARS-CoV-2? Bratisl Lek Listy 121(10):705–711
Fani M et al (2021) The role of miRNAs in COVID-19 disease. Futur Virol 16(4):301–306
Patel CN et al (2021) Identification of potential inhibitors of coronavirus hemagglutinin-esterase using molecular docking, molecular dynamics simulation and binding free energy calculation. Mol Diversity 25(1):421–433
Funding
No funding.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
Authors declare no conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Zandi, M., Soltani, S. Hemagglutinin-esterase cannot be considered as a candidate for designing drug against COVID-19. Mol Divers 25, 1999–2000 (2021). https://doi.org/10.1007/s11030-021-10272-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11030-021-10272-w